American Brain Tumor Association Announces New Board of Directors Officers and Members
Meet the ABTA’s newest Board Members, Laura Aguilar, MD, PhD, and Charles (Chad) Schafer, JD.
Meet the ABTA’s newest Board Members, Laura Aguilar, MD, PhD, and Charles (Chad) Schafer, JD.
Read our top takeaways from the Society for Neuro-Oncology (SNO) Annual Meeting, the world’s largest gathering of neuro-oncology experts.
After losing her husband to GBM in 2022 and receiving her own diagnosis, survivor Beth Kassab didn’t know what to expect attending the largest brain tumor conference in Chicago. Read Beth’s top takeaways:
A champion of the brain tumor community for 50 years running, the American Brain Tumor Association (ABTA) has launched its most ambitious undertaking yet – a five-year, $50-million fundraising campaign called Meet Hope Head On.
The Meet Hope Head On campaign will focus on three pillars: tripling the ABTA’s research investment, doubling the number of patients served, and doubling federal funding for brain tumor research. Throughout its 50-year history, the ABTA has provided vital seed money to fund high-risk, high-reward research grants which have contributed to significant breakthroughs in treating brain tumors by many of the country’s leading researchers.
A first-in-class targeted therapy for low-grade glioma could gain FDA approval as early as spring 2024. Here are three things you should know about the emerging drug “vorasidenib.”
Meet the newly-appointed ABTA Board Chair and Member and discover what they’re hopeful for in their new roles.
The American Brain Tumor Association (ABTA) today announced a new partnership with Brain Tumour Foundation of Canada (BTFC) to accelerate brain tumor research. Through this partnership, BTFC will invest in the ABTA research program to co-fund a research project in Canada, focused on improving resection for low-grade glioma.
American Brain Tumor Association
8550 W. Bryn Mawr Ave. Ste 550
Chicago, IL 60631